Patients with BRCA 1/2 mutations not at increased risk for anthracycline-induced cardiotoxicity
the ONA take:
According to a new study presented last week at the 2014 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas, researchers from Georgetown Lombardi Comprehensive Cancer Center and MedStar Heart & Vascular Institute in Washington, D.C., have found that patients with BRCA 1/2 gene mutations do not have an increased risk of anthracycline-induced cardiac toxicity compared with women who do not have the gene mutations.
The study was prompted by findings of preclinical studies that suggested otherwise. For the study, researchers enrolled 81 patients, 39 of whom were BRCA 1/2 carriers and 42 did not have the mutation. Patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer and metastatic disease were not included in the study. Patients with a history of hypertension were excluded as well.
To determine cardiotoxicity, patients had an echocardiogram following anthracycline therapy to determine left ventricular ejection fraction (LVEF) and global longitudinal strain (GLS). Both are measurements to determine cardiac function.
Results showed that 91% of women had a normal LVEF and 85% had a normal GLS, which were measured on average 45 months after therapy. Only one patient with BRCA 1/2 mutation had borderline reduced LVEF.
BRCA 1/2 gene mutations do not have an increased risk of anthracycline-induced cardiac toxicity.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|